{"id":390687,"date":"2018-05-11T00:00:00","date_gmt":"2018-05-11T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/algoim0044-2018-biopharma-crohns-disease-treatment-algorithms-claims-data-analysis-pediatric-us-2018\/"},"modified":"2026-03-31T10:48:35","modified_gmt":"2026-03-31T10:48:35","slug":"algoim0044-2018-biopharma-crohns-disease-treatment-algorithms-claims-data-analysis-pediatric-us-2018","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/algoim0044-2018-biopharma-crohns-disease-treatment-algorithms-claims-data-analysis-pediatric-us-2018\/","title":{"rendered":"Crohn&#8217;s Disease | Treatment Algorithms: Claims Data Analysis | Pediatric | US | 2018"},"content":{"rendered":"<p>Conventional agents (e.g., immunosuppressants, 5-<abbr data-original-title=\"aminosalicylate\" title=\"\">ASA<\/abbr>s) have long been used to treat pediatric Crohn\u2019s disease (<abbr data-original-title=\"Crohn's disease\" title=\"\">CD<\/abbr>). Among the\u00a0<abbr data-original-title=\"tumor necrosis factor\" title=\"\">TNF<\/abbr>-\u03b1 inhibitors, Janssen\/Merck\u2019s Remicade and AbbVie\/Eisai\u2019s Humira are the most commonly used biologics in moderate to severe pediatric\u00a0<abbr data-original-title=\"Crohn's disease\" title=\"\">CD<\/abbr>. The newer drugs (i.e., Takeda\u2019s Entyvio and Janssen\u2019s Stelara), approved for adult\u00a0<abbr data-original-title=\"Crohn's disease\" title=\"\">CD<\/abbr>, offer alternative treatment options, especially for\u00a0<abbr data-original-title=\"tumor necrosis factor\" title=\"\">TNF<\/abbr>-\u03b1 refractory patients; however, these drugs are not approved in pediatric\u00a0<abbr data-original-title=\"Crohn's disease\" title=\"\">CD<\/abbr>. Still, given the limited treatment options for pediatric\u00a0<abbr data-original-title=\"Crohn's disease\" title=\"\">CD<\/abbr>\u00a0patients who fail\u00a0<abbr data-original-title=\"tumor necrosis factor\" title=\"\">TNF<\/abbr>-\u03b1 inhibitors, physicians may turn to these novel therapies for some patients. Indeed, the availability of these newer agents will likely make the treatment landscape more complex.<\/p>\n<p><strong>QUESTIONS ANSWERED:<\/strong><\/p>\n<ul>\n<li>What patient share do key therapies and brands garner by line of therapy in newly diagnosed pediatric\u00a0<abbr data-original-title=\"Crohn's disease\" title=\"\">CD<\/abbr>\u00a0patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed pediatric\u00a0<abbr data-original-title=\"Crohn's disease\" title=\"\">CD<\/abbr>\u00a0patients?<\/li>\n<li>How have Entyvio\u00a0and Stelara been integrated into the treatment algorithm?<\/li>\n<li>What proportion of pediatric\u00a0<abbr data-original-title=\"Crohn's disease\" title=\"\">CD<\/abbr>\u00a0patients receive drug therapy within 365 days of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within 365 days of diagnosis?<\/li>\n<li>What percentage of pediatric\u00a0<abbr data-original-title=\"Crohn's disease\" title=\"\">CD<\/abbr>\u00a0patients are treated with monotherapy versus combination therapy? What are the most widely used combination therapies?<\/li>\n<li>What are the product-level compliance and persistency rates among drug-treated pediatric patients with\u00a0<abbr data-original-title=\"Crohn's disease\" title=\"\">CD<\/abbr>?<\/li>\n<\/ul>\n<p><strong>PRODUCT DESCRIPTION:\u00a0<\/strong><\/p>\n<p><em>Treatment Algorithms: Claims Data Analysis<\/em>\u00a0provides detailed analysis of brand usage across different lines of therapy using real-world data patient-level claims data so you can accurately assess your source of business and quantify areas of opportunity for increasing your brand share.<\/p>\n","protected":false},"template":"","class_list":["post-390687","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-crohns-disease","biopharma-product-treatment-algorithms-claims-data-analysis","biopharma-geography-us","biopharma-date-920"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390687","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390687\/revisions"}],"predecessor-version":[{"id":393811,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390687\/revisions\/393811"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390687"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}